Teva (TEVA) Sues Forest Labs (FRX) Over Alzheimer's Disease Drug
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $13.23 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) is said to have filed a lawsuit against Forest Labs (NYSE: FRX) over patent infringement, according to Bloomberg headlines.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
- DT Midstream (DTM) Wins Ruling Over Energy Transfer (ET) Pipeline Amid Dispute - Bloomberg
- Norfolk Southern agrees to pay $600 million to settle Ohio derailment lawsuit
Create E-mail Alert Related Categories
Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
